Dieses Anti-FLT4-Antikörper ist ein Kaninchen Polyklonal-Antikörper zur Detektion von FLT4 in WB, ELISA, IP und IHC (af). Geeignet für Human. Dieses Primary Antibody wurde in 1 Publikation zitiert.
FLT4
Reaktivität: Human
IHC, ELISA, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Western Blot: Use 1-5 μg/mL
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.
Buffer
PBS
Handhabung
Centrifuge vial prior to opening.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.
Haltbarkeit
24 months
Liu, Li, Zhang, Rao, Liang, Liu: "The defect of both angiogenesis and lymphangiogenesis is involved in preeclampsia." in: Placenta, Vol. 36, Issue 3, pp. 279-86, (2015) (PubMed).
Target
FLT4
(Fms-Related Tyrosine Kinase 4 (FLT4))
Andere Bezeichnung
VEGFR-3/FLT-4
Hintergrund
Vascular endothelial growth factor receptor-3, FLT4, PCL, LMPH1A, VEGFR3, fms-related tyrosine kinase 4,Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1-D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelia cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.